Clinical Trial Update: Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and immunogenicity of a meningococcal B vaccine in 2-month-old infants. Results were completed and posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infection
• Meningococcal Meningitis

Drugs mentioned

• MenB vaccine (Meningococcal group B vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Meningitis, Meningococcal Infections | Phase 2 | Status: COMPLETED | Results posted: 2015-03-04